[go: up one dir, main page]

MA54969A1 - Anticorps monoclonal se liant spécifiquement à gitr - Google Patents

Anticorps monoclonal se liant spécifiquement à gitr

Info

Publication number
MA54969A1
MA54969A1 MA54969A MA54969A MA54969A1 MA 54969 A1 MA54969 A1 MA 54969A1 MA 54969 A MA54969 A MA 54969A MA 54969 A MA54969 A MA 54969A MA 54969 A1 MA54969 A1 MA 54969A1
Authority
MA
Morocco
Prior art keywords
gitr
relates
monoclonal antibody
specifically binding
antibody specifically
Prior art date
Application number
MA54969A
Other languages
English (en)
Inventor
Iakov Iurevich Ustiugov
Roman Alekseevich Ivanov
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Andrei Borisovich Ulitin
Olesya Nikolaevna Kozlova
Aleksandr Andreevich Gordeev
Ksenia Mihailovna Burnysheva
Anastasia Nikolaevna Ishutinova
Aleksandra Aleksandrovna Sozonova
Sergei Andreevich Ageev
Aleksandr Nikolaevich Doronin
Vladimir Sergeevich Tsympilov
Ivan Vladimirovich Mitroshin
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA54969A1 publication Critical patent/MA54969A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte au domaine des biotechnologies et concerne notamment des anticorps et leurs fragments liant à l'antigène, ainsi que leur utilisation. L'invention concerne plus précisément des anticorps monoclonaux se liant spécifiquement à gitr. L'invention concerne également un acide nucléique codant pour cet anticorps ou un fragment de liaison d'antigène de celui-ci, un vecteur d'expression, un procédé de production d'un anticorps et l'utilisation d'un anticorps pour traiter des maladies ou des troubles associés aux gitr.
MA54969A 2019-04-23 2020-04-23 Anticorps monoclonal se liant spécifiquement à gitr MA54969A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019112296A RU2734432C1 (ru) 2019-04-23 2019-04-23 Моноклональное антитело, которое специфически связывается с GITR
PCT/RU2020/050080 WO2020218951A2 (fr) 2019-04-23 2020-04-23 Anticorps monoclonal se liant spécifiquement à gitr

Publications (1)

Publication Number Publication Date
MA54969A1 true MA54969A1 (fr) 2022-08-31

Family

ID=69821666

Family Applications (2)

Application Number Title Priority Date Filing Date
MA54969A MA54969A1 (fr) 2019-04-23 2020-04-23 Anticorps monoclonal se liant spécifiquement à gitr
MA55390A MA55390B1 (fr) 2019-04-23 2020-06-30 Dispositif pour découper l'adn à base de la protéine cas9 à partir de la bactérie pasteurella pneumotropica

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA55390A MA55390B1 (fr) 2019-04-23 2020-06-30 Dispositif pour découper l'adn à base de la protéine cas9 à partir de la bactérie pasteurella pneumotropica

Country Status (22)

Country Link
US (1) US20220213209A1 (fr)
EP (1) EP3964525A4 (fr)
JP (1) JP2022532991A (fr)
KR (1) KR20220010501A (fr)
CN (1) CN110903392B (fr)
AR (1) AR118763A1 (fr)
AU (1) AU2020261207A1 (fr)
BR (1) BR112021021281A2 (fr)
CA (1) CA3137822A1 (fr)
CL (1) CL2021002792A1 (fr)
CO (1) CO2021014153A2 (fr)
EA (1) EA202192907A1 (fr)
IL (1) IL287531A (fr)
JO (1) JOP20210286A1 (fr)
MA (2) MA54969A1 (fr)
MX (1) MX2021012962A (fr)
PE (1) PE20220144A1 (fr)
RU (1) RU2734432C1 (fr)
TW (1) TWI803718B (fr)
UY (1) UY38672A (fr)
WO (1) WO2020218951A2 (fr)
ZA (1) ZA202109374B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111732658B (zh) * 2020-06-28 2022-04-26 英诺湖医药(杭州)有限公司 一组gitr单克隆抗体及其医药用途
CN112540179B (zh) * 2020-08-06 2023-07-07 武汉天德生物科技有限公司 一种测试ApoE4蛋白含量的ELISA试剂盒
CN112362876B (zh) * 2020-08-06 2023-12-15 武汉天德生物科技有限公司 一种检测早期老年痴呆症的胶体金试纸条及其制备方法
CN111763257B (zh) * 2020-09-01 2020-12-15 北京百奥赛图基因生物技术有限公司 抗gitr抗体及其用途
CN114891110A (zh) * 2020-12-31 2022-08-12 中元汇吉生物技术股份有限公司 特异性结合人IgG4的蛋白及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1319120C (fr) 1985-04-01 1993-06-15 John Henry Kenten Lignee cellulaire myelomateuse transformee et expression d'un gene codant pour un polypeptide d'eucaryote a l'aide de cette lignee
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
RU2369636C2 (ru) * 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
EP2385069A3 (fr) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Variantes de polypeptides Fc se liant au récepteur (FcRn) néonatal, protéines Fc dimèriques et procédés correspondants
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
WO2007005612A2 (fr) 2005-07-01 2007-01-11 Medimmune, Inc. Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine
AU2010289677B2 (en) * 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
KR20220116578A (ko) * 2014-05-28 2022-08-23 아게누스 인코포레이티드 항-gitr 항체 및 이의 사용 방법
KR101923326B1 (ko) 2014-06-06 2018-11-29 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
GB2557389B (en) * 2015-01-14 2020-12-23 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
WO2017068186A1 (fr) 2015-10-22 2017-04-27 Ablynx Nv Agonistes de gitr
US20200123265A1 (en) 2015-12-02 2020-04-23 Agenus Inc. Anti-gitr antibodies and methods of use thereof
US10738126B2 (en) 2016-06-10 2020-08-11 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
CN109641967A (zh) * 2016-07-01 2019-04-16 戊瑞治疗有限公司 用GITR激动剂和CpG的组合的抗肿瘤疗法
WO2018031400A1 (fr) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation
CA3042727A1 (fr) * 2016-11-19 2018-05-24 Potenza Therapeutics, Inc. Proteines de liaison a un antigene anti-gitr et leurs procedes d'utilisation
MX2019010458A (es) * 2017-03-03 2020-01-20 Rinat Neuroscience Corp Anticuerpos anti-gitr y metodos de uso de los mismos.
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途

Also Published As

Publication number Publication date
CO2021014153A2 (es) 2021-10-29
JP2022532991A (ja) 2022-07-21
CN110903392A (zh) 2020-03-24
AU2020261207A1 (en) 2021-12-23
CL2021002792A1 (es) 2022-06-24
IL287531A (en) 2021-12-01
EA202192907A1 (ru) 2022-01-25
CN110903392B (zh) 2024-02-13
ZA202109374B (en) 2022-12-21
TW202100554A (zh) 2021-01-01
JOP20210286A1 (ar) 2023-01-30
MA55390A1 (fr) 2022-05-31
RU2734432C1 (ru) 2020-10-16
PE20220144A1 (es) 2022-01-27
AR118763A1 (es) 2021-10-27
CA3137822A1 (fr) 2020-10-29
WO2020218951A3 (fr) 2020-12-24
WO2020218951A2 (fr) 2020-10-29
KR20220010501A (ko) 2022-01-25
EP3964525A4 (fr) 2022-12-28
MA55390B1 (fr) 2022-10-31
US20220213209A1 (en) 2022-07-07
MX2021012962A (es) 2021-12-15
UY38672A (es) 2020-10-30
BR112021021281A2 (pt) 2022-03-08
TWI803718B (zh) 2023-06-01
EP3964525A2 (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
MA54969A1 (fr) Anticorps monoclonal se liant spécifiquement à gitr
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
MA54405B1 (fr) Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène
MA44547A1 (fr) Anticorps anti-pd-1,procédé de leur production et de leur utilisation
MA31838B1 (fr) Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations
MA34647B1 (fr) Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
TN2018000419A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof.
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
WO2018194496A3 (fr) Anticorps monoclonal à pd-l1
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
WO2021212049A3 (fr) Anticorps monoclonaux anti-sars-cov-2
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
MX2023009244A (es) Anticuerpos contra la proteina espicular de coronavirus.
SA520420582B1 (ar) Cd3 أجسام مضادة خاصة لـ واستخداماتها
MA50128A1 (fr) Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation
CA3179819A1 (fr) Anticorps anti-glycoproteine spike du sars-cov 2 et leurs fragments de liaison a l'antigene
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
ZA202305072B (en) Cd1a antibodies and uses thereof
BR112022002142A2 (pt) Anticorpos anti-bdca-2
MA45831B1 (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
WO2023205239A3 (fr) Agent thérapeutique à base d'adn codant pour un anticorps ou un fragment de liaison à un antigène